首页 | 本学科首页   官方微博 | 高级检索  
     


Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T‐cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434
Authors:Stuart S. Winter MD  Kimberly P. Dunsmore MD  Meenakshi Devidas PhD  Nancy Eisenberg MPH  Barbara L. Asselin MD  Brent L. Wood MD  PhD  Marcia S. Leonard RN RN  PNP  John Murphy Pharm D  Julie M. Gastier‐Foster PhD  Andrew J. Carroll PhD  Nyla A. Heerema PhD  Mignon L. Loh MD  Elizabeth A. Raetz MD  Naomi J. Winick MD  William L. Carroll MD  Stephen P. Hunger MD
Affiliation:1. University of New Mexico Health Sciences Center, Albuquerque;2. University of Virginia Children's Hospital, Charlottesville, Virginia;3. Biostatistics, the University of Florida, Gainesville, Florida;4. University of Rochester, Rochester, New York;5. Seattle Children's Hospital, Seattle, Western Australia;6. C S Mott Children's Hospital, Ann Arbor, Michigan;7. Princess Margaret Hospital for Children, Perth, Australia;8. Nationwide Children's Hospital, Columbus, Ohio;9. Ohio State University, Columbus, Ohio;10. University of Alabama at Birmingham, Birmingham, Alabama;11. UCSF Medical Center – Parnassus, San Francisco, California;12. University of Utah, Primary Children's Hospita, Salt Lake City;13. University of Texas Southwestern Medical Center, Dallas, Texas;14. Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York;15. University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado.
Abstract:
Keywords:BFM chemotherapy regimen  nelarabine  T‐ALL
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号